Trial Profile
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Pepinemab (Primary)
- Indications Neuroblastoma; Osteosarcoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 28 Sep 2023 Planned End Date changed from 31 Dec 2025 to 22 Sep 2024.
- 22 Apr 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2025.
- 09 Mar 2021 Planned End Date changed from 19 Sep 2021 to 31 Dec 2021.